All In Biotech

Drug Trial Radar · NCT03001869

68Ga-PSMA PET/CT in Prostate Cancer

The Safety and Efficacy of 68Ga-HBED-CC-PSMA PET/CT in Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

540

Actual

Start

Jul 1, 2017

Primary completion

Jul 1, 2023

Study completion Jul 1, 2023

Sponsor

Lead sponsor
Sir Mortimer B. Davis - Jewish General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 23, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to replicate the safety and efficacy of 68Ga-PSMA PET/CT and as a diagnostic and decision making tool in the management prostate cancer patients.The primary endpoints of the study are the incidence of adverse events (AE) in the study population up to 7 days following the scan, and the sensitivity and specificity of 68Ga-PSMA PET/CT vs CT on a per-patient and per-lesion basis.

Conditions

  • Prostate Cancer

Interventions

  • 68Ga-HBED-CC-PSMA PET/CTDrug

    68Ga-HBED-CC-PSMA PET/CT Scan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of Ga68-PSMA PET/CT imaging as measured by the incidence of adverse events (AE)Time frame: 7 days
  2. Efficacy of Ga68-PSMA PET/CT imaging as measured by sensitivity and specificity vs CT on a per patient basis as compared to standard of truthTime frame: 12 months
  3. Efficacy of Ga68-PSMA PET/CT imaging as measured by sensitivity and specificity vs CT on a per lesion basis as compared to standard of truthTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jewish General Hospital

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.